source
- Coultreon banks $125M to support testing of former Galapagos immune drugBacked by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.BioPharma Dive · 4mo ago↗ source
- Predicting consequences of new hepatitis B vaccine recsNew data on public trust in science, AI and mental health, and other news from Morning RoundsSTAT · 4mo ago↗ source
- Galapagos spinout Coultreon raises $125M for new take on SIK inhibitionCoultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune disea…Endpoints